secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0000950170-24-034271
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO and CFO adopt Rule 10b5-1 trading plans for up to 159,672 shares
--------------------------------------------------------------------

- CEO Yuval Cohen plan: sale of up to 117,066 shares beginning June 13, 2024, ending March 15, 2025.
- CFO Sean Moran plan: sale of up to 42,606 shares, same start and termination dates.
- Both plans adopted March 15, 2024, disclosed via 8-K on March 20, 2024.
- Plans intended to satisfy affirmative defense of Rule 10b5-1(c).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024034271/0000950170-24-034271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024034271/crbp-20240320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer